Leerink Partnrs Has Negative Outlook of TRVI FY2024 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for Trevi Therapeutics in a report issued on Tuesday, January 21st. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings of ($0.49) per share for the year, down from their previous estimate of ($0.48). The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.49) EPS and FY2026 earnings at ($0.48) EPS.

Several other research analysts have also weighed in on TRVI. D. Boral Capital reissued a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a report on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and issued a $8.00 price target on shares of Trevi Therapeutics in a research report on Thursday, December 12th. HC Wainwright upped their price objective on Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a research note on Thursday, December 12th. Finally, B. Riley restated a “buy” rating and issued a $6.00 target price on shares of Trevi Therapeutics in a research report on Monday, October 7th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $9.31.

Trevi Therapeutics Stock Performance

Shares of NASDAQ:TRVI opened at $3.78 on Thursday. The company has a fifty day simple moving average of $3.52 and a 200 day simple moving average of $3.20. Trevi Therapeutics has a 12-month low of $1.30 and a 12-month high of $4.68.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same period in the prior year, the firm posted ($0.08) earnings per share.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. GSA Capital Partners LLP acquired a new position in shares of Trevi Therapeutics in the 3rd quarter worth approximately $409,000. Geode Capital Management LLC grew its position in Trevi Therapeutics by 10.2% in the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock worth $4,223,000 after buying an additional 117,418 shares during the last quarter. Fred Alger Management LLC acquired a new position in Trevi Therapeutics in the third quarter worth approximately $256,000. JPMorgan Chase & Co. increased its holdings in shares of Trevi Therapeutics by 220.6% in the third quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock valued at $336,000 after buying an additional 69,167 shares in the last quarter. Finally, Barclays PLC lifted its position in shares of Trevi Therapeutics by 180.8% during the 3rd quarter. Barclays PLC now owns 95,232 shares of the company’s stock valued at $319,000 after acquiring an additional 61,317 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.